TNF and inflammatory bowel disease: Pharmacological interventions commonly used in IBD management—such as 5-aminosalicylic acid, thiopurine, nonsteroidal anti-inflammatory drugs, and tumor necrosis factor-α inhibitors—have been associated with reduced CRC risk 56.